Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 11,078 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares of the company’s stock, valued at $7,635,587.19. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Tyra Biosciences Trading Down 1.7 %

NASDAQ TYRA traded down $0.29 during trading hours on Friday, reaching $16.39. 523,453 shares of the company traded hands, compared to its average volume of 186,846. Tyra Biosciences, Inc. has a 12 month low of $10.60 and a 12 month high of $29.60. The stock has a market capitalization of $865.56 million, a PE ratio of -9.70 and a beta of 1.01. The company has a 50 day moving average of $22.51 and a two-hundred day moving average of $19.87.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TYRA. Oppenheimer & Co. Inc. bought a new position in Tyra Biosciences during the 1st quarter valued at $977,000. Vanguard Group Inc. lifted its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. BVF Inc. IL lifted its position in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares during the last quarter. Kynam Capital Management LP lifted its position in shares of Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after buying an additional 175,000 shares during the last quarter. Finally, RA Capital Management L.P. lifted its position in shares of Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Piper Sandler started coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Oppenheimer upped their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Finally, HC Wainwright upped their target price on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.40.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.